B

BioMarin

Orphan-drug biotech focused on rare diseases

Overview

BioMarin Pharmaceutical focuses on developing and selling medicines for people with rare genetic diseases. It creates orphan drugs—therapies designed for small patient populations—and has a lineup of approved treatments such as Vimizim (enzyme replacement for Morquio A syndrome), Naglazyme (enzyme replacement for MPS VI), and Kuvan (a cofactor therapy for phenylketonuria). The company’s products work by supplying missing or defective enzymes or cofactors in patients’ bodies, helping to treat the underlying metabolic problems. BioMarin differentiates itself through its specialization in rare diseases, building a pipeline of product candidates across stages of development and selling primarily to specialty pharmacies and hospitals. Its goal is to provide approved, accessible treatments for patients with limited options and to grow its portfolio to cover more rare genetic conditions.

Work here?Claim your company

About BioMarin

Simplify's Rating
Not yet rated

We're working on gathering enough insights on this company, check back soon!

Industries

BiotechnologyHealthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Rafael, CA

Founded

1997

Get referred to BioMarin

See people who can refer or advise you

Funding

Total Funding

$1.9B

Above

Industry Average

Funded Over

9 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison Coming Soon

Growth & Insights

6 month growth

0%

1 year growth

0%

2 year growth

0%

Recently Posted Jobs

Sign up to get curated job recommendations

BioMarin is Hiring for 83 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs